Cathepsin D as biomarker in cerebrospinal fluid of nusinersen‐treated patients with spinal muscular atrophy. (4th May 2022)

• Record Type: Journal Article
• Authors: Schorling, David C.; Kölbel, Heike; Hentschel, Andreas; Pechmann, Astrid; Meyer, Nancy; Wirth, Brunhilde; Rombo, Roman; Sickmann, Albert; Kirschner, Janbernd; Schara‐Schmidt, Ulrike; Lochmüller, Hanns; Roos, Andreas
• Other Names: Abele Thea Beatrice investigator.; Andres Barbara investigator.; Angelova‐Toshkina Daniela investigator.; Baum Petra investigator.; Baum Tobias investigator.; Baumann Matthias investigator.; Baumgartner Manuela investigator.; Baur Ute investigator.; Becker Benedikt investigator.; Behring Bettina investigator.; Bernert Günther investigator.; Birsak Theresa investigator.; Bellut Julia investigator.; Bertsche Astrid investigator.; Blankenburg Markus investigator.; Blaschek Astrid investigator.; Braun Nathalie investigator.; Braun Sarah investigator.; Burgenmeister Nadine investigator.; Claus Nicole investigator.; Cordts Isabell investigator.; de Vries Heike investigator.; Deba Timo investigator.; Marina Adela Della investigator.; Denecke Jonas investigator.; Deschauer Marcus investigator.; Dörnbrack Katharina investigator.; Driemeyer Joenna investigator.; Eckenweiler Matthias investigator.; Eisenkölbl Astrid investigator.; Fiedler Barbara investigator.; Fischer Michal investigator.; Flotats‐Bastardas Marina investigator.; Freigang Maren investigator.; Friese Johannes investigator.; Gaiser Philippa investigator.; Gebert Axel investigator.; Geitmann Stephanie investigator.; Goldhahn Klaus investigator.; Grässl Michael investigator.; Gröning Kristina investigator.; Grosskreutz Julian investigator.; Gruber‐Sedlmayr Ursula investigator.; Guillemot Helene investigator.; Günther René investigator.; von der Hagen Maja investigator.; Hagenacker Tim investigator.; Hahn Andreas investigator.; Hartmann Hans investigator.; Hiebeler Miriam investigator.; Hobbiebrunken Elke investigator.; Friedrich Hoffmann Georg investigator.; Holtkamp Britta investigator.; Holzwarth Dorothea investigator.; Horber Veronka investigator.; Husain Ralf A. investigator.; Illsinger Sabine investigator.; Jansen Eva investigator.; Johannsen Jessika investigator.; Kaindl Angela investigator.; Kaiser Nadja investigator.; Klamroth Jennifer investigator.; Christoph Koch Jan investigator.; Köhler Cornelia investigator.; Koelker Stefan investigator.; Kolzter Kirsten investigator.; Korschinsky Brigitte investigator.; Küpper Hanna investigator.; Langer Thorsten investigator.; Lehnert Ilka investigator.; Lingor Paul investigator.; Löscher Wolfgang N. investigator.; LoudoviciüKrug Dana investigator.; Martakis Kyriakos investigator.; Mayer Iris investigator.; Metelmann Moritz investigator.; Meyer Sascha investigator.; von Moers Arpad investigator.; Mueller‐Kaempffer Katharina investigator.; Müller Monika investigator.; Müller Petra investigator.; Müller‐Felber Wolfgang investigator.; Neuwirth Christoph investigator.; Niederschweiberer Johanna investigator.; Nolte Anja investigator.; Odorfer Thorsten investigator.; Omran Heymut investigator.; Pauschek Josefine investigator.; Pickrodt Katrin investigator.; Plecko Barbara investigator.; Pühringer Manuel investigator.; Quinten Anna Lisa investigator.; Rappold Mika investigator.; Reihle Christof investigator.; Reinhardt Tabea investigator.; Rödiger Annekathrin investigator.; Roetmann Gerda investigator.; Saffari Afshin investigator.; Schimmel Mareike investigator.; Schlachter Kurt investigator.; Schneider Joanna investigator.; Schoene‐Bake Christoph investigator.; Schreiber Gudrun investigator.; Schwartz Oliver investigator.; Schwerin‐Nagel Anette investigator.; Schwersenz Inge investigator.; Smitka Martin investigator.; Stein Sabine investigator.; Steinbach Robert investigator.; Steiner Elisabeth investigator.; Steuernagel Daniela investigator.; Stögmann Eva investigator.; Stolte Benjamin investigator.; Stoltenburg Corinna investigator.; Stüve Burkhard investigator.; Tassoni Adrian investigator.; Theophil Manuela investigator.; Thiele Simone investigator.; Topakian Raffi investigator.; Trollmann Regina investigator.; Türk Matthias investigator.; van der Stam Lieske investigator.; Vill Katharina investigator.; Vogt Sibylle investigator.; Vollmann Peter investigator.; Walter Maggie C. investigator.; Warken Birgit investigator.; Weber Markus investigator.; Weiler Markus investigator.; Weiß Claudia investigator.; Weiss Deike investigator.; Weiss Simone investigator.; Wenzel Franziska investigator.; Wider Sabine investigator.; Wiebe Nils investigator.; Wiegand Gert investigator.; Wilichowski Ekkehard investigator.; Wilken Bernd investigator.; Wochner Katarzyna investigator.; Zeiner Fiona investigator.; Zeisler Daniela investigator.; Zeller Daniel investigator.; Zemlin Michael investigator.; Ziegler Andreas investigator.;
• Is Part Of: European journal of neurology. Volume 29:Number 7(2022)
• Page Start: 2084
• Page End: 2096
• Publication Date: 2022-05-04
• Subjects: amyloid‐associated disease -- biomarkers -- cathepsin D -- cerebrospinal fluid -- spinal muscular atrophy; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.15331
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract: Background and purpose: The therapeutic landscape of spinal muscular atrophy (SMA) has changed dramatically during the past 4 years, but treatment responses differ remarkably between individuals, and therapeutic decision‐making remains challenging, underlining the persistent need for validated biomarkers. Methods: We applied untargeted proteomic analyses to determine biomarkers in cerebrospinal fluid (CSF) samples of SMA patients under treatment with nusinersen. Identified candidate proteins were validated in CSF samples of SMA patients by Western blot and enzyme‐linked immunosorbent assay. Furthermore, levels of peripheral neurofilament heavy and light chain were determined. Results: Untargeted proteomic analysis of CSF samples of three SMA type 1 patients revealed the lysosomal protease cathepsin D as a candidate biomarker. Subsequent validation analysis in a larger cohort of 31 pediatric SMA patients (type 1, n = 12; type 2, n = 9; type 3, n = 6; presymptomatically treated, n = 4; age = 0–16 years) revealed a significant decline of cathepsin D levels in SMA patients aged ≥2 months at the start of treatment. Although evident in all older age categories, this decline was only significant in the group of patients who showed a positive motor response. Moreover, downregulation of cathepsin D was evident in muscle biopsies of SMA patients. Conclusions: We identified a decline of cathepsin D levels in CSF samples of SMA patients under nusinersen treatment that was more pronounced in the group of "treatment responders" than in "nonresponders." We believe that our results indicate a suitability of cathepsin D levels as a possible biomarker in SMA also in older patients, in combination with analysis of peripheral neurofilament light chain in adolescents or alone in adult patients. Abstract : Cathepsin D declines in cerebrospinal fluid of nusinersen‐treated spinal muscular atrophy (SMA) patients aged 2 months or older at start of therapy. The decline appears to be associated with response to treatment and indicates suitability as a prognostic biomarker in SMA.